Synthesis and biological evaluation of EC20: A new folate-derived, 99mTc-based radiopharmaceutical

Bioconjugate Chemistry

Volumn 13, Issue 6, 2002, Pages 1200-1210

  Leamon, Christopher P ^a   Parker, Matthew A ^a   Vlahov, Iontcho R ^a   Xu, Le Cun ^a   Reddy, Joseph A ^a   Vetzel, Marilynn ^a   Douglas, Nikki ^a  

^a Endocyte Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS; ORGANIC ACIDS; TUMORS;

BALB/C MICE; BIOLOGICAL EVALUATION; CONCENTRATION-DEPENDENT MANNERS; FOLATE RECEPTOR; FOLATES; FOLIC ACIDS; HIGH AFFINITY; SYNTHESIS EVALUATION; TIME DEPENDENT; TUMOUR CELLS;

CHELATION;

ANIMALIA;

EID: 0036862058     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0200430     Document Type: Article

References (73)

1. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjugate Chem. 7, 56-62.
2. Mathias, C. J., et al. (1996) Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium-67-deferoxamine-folate. J. Nuc. Med., 37 (6), 1003-1008.
3. Mathias, C. J., et al. (1998) Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med., 39, 1579-1585.
4. 99mTc-Ethylenedicysteine-folate: A new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother. Radiopharm. 13 (6), 427-435.
5. 99mTc-HYNIC-folate: A novel receptor-based targeted radiopharmaceutical for tumor imaging. J. Nucl. Med. 40 (9), 1563-1569.
6. 99mTc-OXA-Folate show uptake of both isomers in folate-receptor (+) KB cell lines. Soc. Nucl. Med. Proc. 47th Annual Meeting 41 (5), 119P.
7. Olsen, J. O., et al. (1995) Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin. Nucl. Med. 25 (3), 251-61.
8. Virgolini, I, et al. (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331 (17), 1116-1121.
9. 131I-labeled chimeric monoclonal antibody MOv18 in ovarian cancer patients: A pilot study. Tumor Targeting 4, 179-188.
10. Collins, D. A., Hogenkamp, H. P., and Gebhard, M. W. (1999) Tumor imaging via indium 111-labeled DTPA-adeno-sylcobalamin. Mayo Clin. Proc. 74 (7), 687-91.
11. Modorati, G., et al. (1994) Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: Preliminary results. Br. J. Ophthalmol. 78 (1), 19-23.
12. Seccamani, E., et al. (1989) A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int. J. Radiat. Appl. Instrum. B, 16 (2), 167-170.
13. Colcher, D., et al. (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 82 (14), 1191-1197.
14. Leamon, C. P., Low, P. S. (2001) Folate-mediated targeting: From diagnostics to drug and gene delivery. Drug Discov. Today, 6 (1), 44-51.
15. Konda, S. D., et al. (2000) Development of a tumortargeting MR contrast agent using the high-affinity folate receptor. Invest. Radiol. 35 (1), 50-57.
16. Ladino, C. A., et al. (1997) Folate-maytansinoids: Targetselective drugs of low molecular weight. Int. J. Cancer 73, 859-864.
17. Citro, G., et al. (1994) Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer 69, 463-467.
18. Li, S., Huang, L. (1997) Targeted delivery of antisense oligodeoxynucleotides by LPDII. J. Liposome Res. 7 (1), 63-75.
19. Li, S., Huang, L. (1998) Targeted delivery of antisense oligodeoxynucleotides formulated in a novel lipidic vector. J. Liposome Res. 8 (2), 239-250.
20. Li, S., Deshmukh, H. M., and Huang, L. (1998) Folate-mediated targeting of antisense oligonucleotides to ovarian cancer cells. Pharm. Res. 15 (10), 1540-1545.
21. Leopold, L. H., et al. (1995) Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85 (8), 2162-2170.
22. Leamon, C. P., Low, P. S. (1991) Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U.S.A. 88, 5572-5576.
23. Ward, C. M., Acheson, N., and Seymour, L. M. (2000) Folic acid targeting of protein conjugates into ascites tumor cells from ovarian cancer patients. J. Drug Targeting 8 (2), 119-123.
24. Lu, J. Y., et al. (1999) Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Targeting 7 (1), 43-53.
25. Leamon, C. P.; Low, P. S. (1992) Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267, 24966-24971.
26. Leamon, C. P., Pastan, I., and Low, P. S. (1993) Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells. J. Biol. Chem. 268, 24847-24854.
27. Leamon, C. P., Low, P. S. (1994) Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Targeting 2, 101-112.
28. Kranz, D. M., et al. (1995) Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. Acad. Sci. U.S.A. 92, 9057-9061.
29. Cho, B. K., et al. (1997) Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjugate Chem. 8, 338-346.
30. Kranz, D. M., et al. (1998) Targeting tumor cells with bispecific antibodies and T cells. J. Controlled Release 53, 77-84.
31. Rund, L. A., et al. (1999) Bispecific agents target endogenous murine T cells against human tumor xenografts. Int. J. Cancer 83, 141-149.
32. Lee, R. J., Low, P. S. (1994) Delivery of liposomes into cultured KB cells via folate receptor- mediated endocytosis. J. Biol. Chem. 269, 3198-3204.
33. Lee, R. J., Low, P. S. (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233, 134-144.
34. Vogel, K., et al. (1996) Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J. Am. Chem. Soc. 118 (7), 1581-1586.
35. Rui, Y., et al. (1998) Diplasmenylcholine-folate liposomes: An efficient vehicle for intracellular drug delivery. J. Am. Chem. Soc. 120 (44), 11213-11218.
36. Gabizon, A., et al. (1999) Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: In vitro studies. Bioconjugate Chem. 10 (2), 289-98.
37. Gottschalk, S., et al. (1994) Folate receptor mediated DNA delivery into tumor cells: Potosomal disruption results in enhanced gene expression. Gene Ther. 1, 185-191.
38. Mislick, K. A., et al. (1995) Transfection of folate-polylysine DNA complexes: Evidence for lysosomal delivery. Bioconjugate Chem. 6, 512-515.
39. Douglas, J. T., et al. (1996) Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotech. 14, 1574-1578.
40. Leamon, C. P., Weigl, D., and Hendren, R. W. (1999) Folate copolymer-mediated transfection of cultured cells. Bioconjugate Chem. 10, 947-957.
41. Guo, W., Lee, R. J. (1999) Receptor-targeted gene delivery via folate-conjugated polyethylenimine. PharmSci 1 (4), 19.
42. Reddy, J. A., et al. (1999) Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J. Pharm. Sci. 88 (11), 1112-1118.
43. Reddy, J. A., Low, P. S. (2000) Enhanced folate receptor mediated gene therapy using a novel pH-senistive lipid formulation. J. Controlled Release 64, 27-37.
44. Antich, P., et al. (1994) Imaging of folate receptors with I-125 labeled folate using small animal imaging system built with plastic scintillating optical fibers. J. Nucl. Med. 35, 222 (abstract).
45. Mathias, C. J., et al. (2000) Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjugate Chem. 11 (2), 253-7.
46. Rouschias, G. (1974) Chem. Rev. 74, 531.
47. Westerhof, G. R., et al. (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular structure and biological activity. Mol. Pharm. 48, 459-471.
48. Leamon, C. P., Low, P. S. (1993) Membrane folate-binding proteins are responsible for folate- protein conjugate endocytosis into cultured cells. Biochem. J. 291, 855-860.
49. Eisenhut, M., et al. (1991) J. Labeled Compd. Radiopharm. 29, 1283.
50. Liu, S., et al. (1996) Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: Effects of chelators on properties of [99mTc]-chelator-peptide conjugates. Bioconjugate Chem. 7 (2), 196-202.
51. Liu, S., et al. (1996) Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands. Bioconjugate Chem. 7 (1), 63-71.
52. Fritzberg, A. R., et al. (1988) Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. Pharm. Res. 5 (6), 325-334.
53. Liang, F. H., Virzi, F., and Hnatowich, D. J. (1987) The use of diaminodithiol for labeling small molecules with technetium-99m. Int. J. Radiat. Appl. Instrum. B 14 (1), 63-67.
54. Chianelli, M., et al. (1992) Eur. J. Nucl. Med. 19, 625.
55. Baidoo, K. E., Lever, S. Z., and Scheffel, U., (1994) Bifunctional chelator for facile preparation of neutral technetium complexes. Bioconjugate Chem. 5 (2), 114-118.
56. Eisenhut, M., et al. (1996) Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: Conjugation chemistry, immunoreactivity and kit formulation. J. Nucl. Med. 37 (2), 362-70.
57. Wong, E., et al. (1997) Rhenium (V) and Technetium (V) Oxo complexes of an N (2)N'S peptidic chelator: Evidence of interconversion between the syn and anti conformations. Inorg. Chem. 36 (25), 5799-5808.
58. Francesconi, L. C., et al. (1993) Synthesis and characterization of neutral MVO (M = technetium, rhenium) aminethiol complexes containing a pendant phenylpiperidine group. Inorg. Chem. 32 (14), 3114-3124.
59. Marzilli, L. G., et al. (1994) Linking deprotonation and denticity of chelate ligands. Rhenium (V) Oxo analogues of 99mTechnetium radiopharmaceuticals containing N2S2 chelate ligands. Inorg. Chem. 33 (22), 4850-4860.
60. Leamon, C. P., DePrince, R. B., and Hendren, R. W. (1999) Folate-mediated drug delivery: Effect of alternative conjugation chemistry. J. Drug Targeting 7 (3), 157-169.
61. Antony, A. C. (1992) The biological chemistry of folate receptors. Blood 79 (11), 2807-2820.
62. Jodrell, D. I., et al. (1993) The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice. Biochem. Pharm. 46 (12), 2229-2234.
63. 111In]In-DTPA-Folate, a folate-receptor-targeted radiopharmaceutical. Nuc. Med. Biol. 25, 585-587.
64. Coney, L. R., et al. (1991) Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51, 6125-6132.
65. Weitman, S. D., et al. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52, 3396-3401.
66. Ross, J. F., Chaudhuri, P. K., and Ratnam, M. (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 73, 2432-2443.
67. Weitman, S. D., et al. (1992) Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Research 52, 6708-6711.
68. Weitman, S. D., Frazier, K. M., and Kamen, B. A. (1994) The folate receptor in central nervous system malignancies of childhood. J. Neurol. Oncol. 21, 107.
69. Mattes, M. J., et al. (1990) Patterns of antigen distribution in human carcinomas. Cancer Res. Suppl. 50, 880S.
70. Garin-Chesa, P., et al. (1993) Trophoblast and ovarian cancer antigen LK26. Am. J. Pathol. 142 (2), 557-567.
71. Toffoli, G., et al. (1997) Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 74, 193-198.
72. Holm, J., et al. (1991) High-affinity folate binding in human choroid plexus. Biochem. J. 280, 267-271.
73. Campbell, I. G., et al. (1991) Cancer Res. 51, 5329-5338.